Standard BioTools Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Standard BioTools wird ein jährliches Gewinn- und Umsatzwachstum von 64% bzw. 21.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 87% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -9.8% betragen.

Wichtige Informationen

64.0%

Wachstumsrate der Gewinne

87.0%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	21.1%
Zukünftige Eigenkapitalrendite	-9.8%
Analystenabdeckung	Low
Zuletzt aktualisiert	09 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point

Jun 20

Fluidigm gains after report that activist takes 11% stake, may push for unit sale

May 11

Fluidigm Corporation 2021 Q1 - Results - Earnings Call Presentation

May 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:LAB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	278	9	9	15	3
12/31/2025	232	-64	-60	-57	3
12/31/2024	201	-153	-114	-116	3
3/31/2024	127	-136	-100	-97	N/A
12/31/2023	106	-75	-46	-43	N/A
9/30/2023	105	-76	-52	-48	N/A
6/30/2023	105	-84	-65	-62	N/A
3/31/2023	97	-131	-86	-82	N/A
12/31/2022	98	-190	-93	-89	N/A
9/30/2022	109	-179	-81	-77	N/A
6/30/2022	112	-163	-66	-62	N/A
3/31/2022	124	-117	-54	-47	N/A
12/31/2021	131	-59	-57	-44	N/A
9/30/2021	137	-68	-64	-41	N/A
6/30/2021	148	-60	-58	-36	N/A
3/31/2021	143	-56	-43	-24	N/A
12/31/2020	138	-53	-28	-15	N/A
9/30/2020	126	-48	-20	-17	N/A
6/30/2020	113	-55	-21	-17	N/A
3/31/2020	115	-55	-23	-19	N/A
12/31/2019	117	-65	-38	-35	N/A
9/30/2019	117	-67	-32	-30	N/A
6/30/2019	120	-69	-31	-30	N/A
3/31/2019	118	-71	-30	-29	N/A
12/31/2018	113	-59	-26	-25	N/A
9/30/2018	108	-55	-24	-24	N/A
6/30/2018	104	-56	-29	-28	N/A
3/31/2018	102	-57	-33	-32	N/A
12/31/2017	102	-61	N/A	-24	N/A
9/30/2017	99	-68	N/A	-35	N/A
6/30/2017	97	-72	N/A	-41	N/A
3/31/2017	101	-73	N/A	-40	N/A
12/31/2016	104	-76	N/A	-39	N/A
9/30/2016	110	-71	N/A	-33	N/A
6/30/2016	117	-61	N/A	-32	N/A
3/31/2016	117	-57	N/A	-33	N/A
12/31/2015	115	-53	N/A	-35	N/A
9/30/2015	117	-51	N/A	-34	N/A
6/30/2015	118	-56	N/A	-30	N/A
3/31/2015	117	-53	N/A	-22	N/A
12/31/2014	116	-53	N/A	-23	N/A
9/30/2014	104	-47	N/A	-16	N/A
6/30/2014	92	-37	N/A	-8	N/A
3/31/2014	82	-28	N/A	-11	N/A
12/31/2013	71	-17	N/A	-2	N/A
9/30/2013	66	-15	N/A	-8	N/A
6/30/2013	60	-15	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LABDie Einnahmen des Unternehmens (21.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: LABDie Einnahmen des Unternehmens (21.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: LAB wird voraussichtlich in 3 Jahren unrentabel sein.

Standard BioTools Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024

Consensus EPS estimates upgraded to US$0.43 loss

Forecast to breakeven in 2026

Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024

Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023

Standard BioTools Inc. Provides Earnings Guidance for the Year 2023

Recent updates

Standard BioTools Inc., Annual General Meeting, Jun 27, 2024

Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024

Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024

Standard BioTools Inc. Announces Operational Restructuring Plan

Now 21% undervalued

Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging

Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Consensus EPS estimates upgraded to US$0.43 loss

Chief Strategy Officer notifies of intention to sell stock

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Forecast to breakeven in 2026

Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024

New major risk - Financial position

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

New major risk - Revenue and earnings growth

Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023

High number of new directors

Senior VP & CFO recently bought US$194k worth of stock

Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System

Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer

First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022)

Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors

Chief Financial Officer exercised options and sold US$58k worth of stock

Standard BioTools Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021)

Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023

Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer

Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares.

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021)

Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022

Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021)

Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022

Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022

Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary

Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations

Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Standard BioTools Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$6.00

Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022

Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging

Independent Director exercised options to buy US$80k worth of stock.

Fluidigm Corporation Announces Board Changes

Fluidigm Corporation Announces Management Changes

Price target decreased to US$6.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Fluidigm Corporation: Investment Opportunity

Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

President exercised options and sold US$51k worth of stock

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.083 loss in 3Q 2020)

Fluidigm Corporation Announces the Publication of New Data Further Validating the Potential of Its Mass Cytometry Technologies

President exercised options and sold US$74k worth of stock

Price target increased to US$11.00

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.18 loss in 2Q 2020)

Fluidigm Corporation Revises Earnings Guidance for the Fiscal Year 2021

Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point

Fluidigm Corporation Announces Launch of CyTOF XT

President exercised options and sold US$493k worth of stock